The global phase 3 CAPItello-291 study subsequently enrolled patients with HR-positive/HER2-negative advanced breast cancer and disease progression during or after treatment with aromatase inhibitors across 19 countries13. The gene discussed is CYP19A1; the disease is breast carcinoma.